Real-world use, safety, and patient experience of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases

   Article full text  The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.  The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite). </p